Experimental weight loss drugs are being sold online for "research use only"—but many are injecting them at home.

Novo Nordisk just announced Wegovy for $499/month on its direct-to-consumer platform—but is this price cut really a game-changer?

Explore Medicare's groundbreaking decision to negotiate Ozempic pricing in PoundsPunch Periodical 2025.01.

Weight-Loss Drug Wars Heat Up, PBM Reform Stalls, and Insurers Push Back

Biden’s Weight-Loss Drug Proposal Faces Trump-Era Challenges, Ireland’s Crackdown on Counterfeits, and China’s Next-Gen GLP-1 Innovations

Caremark, Express Scripts, and OptumRx Face Allegations of Rigging the Rebate System

New Proposal to Expand Medicare Coverage Raises Questions on Cost and Potential Savings

Medicare’s Lower Drug Premiums, Lilly’s Shortage Supply Resolved While Compounding Pharmacies Still in Play

A Heated Exchange on the Super Star Weight Loss Drugs' Price, Big Pharma and PBM's Finger-Pointing Game

Commercial Insurance Dominated Weight Loss Prescriptions, Medicare May Target Wegovy for Price Cuts, FDA Reported Eased Drug Shortages

House Bill to Expand Medicare Weight Loss Drug Coverage, The Novo Nordisk CEO to Testify in Senate, Lilly’s Approval in China and More

Explorando nuevos medicamentos, el papel emergente de China e India y el escrutinio del Senado de los Estados Unidos sobre Ozempic y Wegovy

Navegando el cambio: Wegovy y otros medicamentos ahora son más accesibles según las reglas revisadas de Medicare

Medicamento para bajar de peso y disfunción eréctil, nueva fábrica de Eli Lilly, recuperación de peso después de dejar de usar el medicament